Janssen Seeks Patent Trial To Halt Celltrion Biosimilar
Janssen Biotech on Tuesday told a Massachusetts federal judge that it has "powerful evidence" showing patent infringement involving Celltrion's newly approved biosimilar Inflectra and wants a trial later this year to...To view the full article, register now.
Already a subscriber? Click here to view full article